• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于患者报告的不良事件通用术语标准的肺癌治疗患者报告症状监测版本选择子集:混合方法研究

Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study.

作者信息

Veldhuijzen Evalien, Walraven Iris, Belderbos José

机构信息

Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.

Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands.

出版信息

JMIR Cancer. 2021 Sep 14;7(3):e26574. doi: 10.2196/26574.

DOI:10.2196/26574
PMID:34519658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8479599/
Abstract

BACKGROUND

The Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item library covers a wide range of symptoms relevant to oncology care. There is a need to select a subset of items relevant to specific patient populations to enable the implementation of PRO-CTCAE-based symptom monitoring in clinical practice.

OBJECTIVE

The aim of this study is to develop a PRO-CTCAE-based subset relevant to patients with lung cancer that can be used for monitoring during multidisciplinary clinical practice.

METHODS

The PRO-CTCAE-based subset for patients with lung cancer was generated using a mixed methods approach based on the European Organization for Research and Treatment of Cancer guidelines for developing questionnaires, comprising a literature review and semistructured interviews with both patients with lung cancer and health care practitioners (HCPs). Both patients and HCPs were queried on the relevance and impact of all PRO-CTCAE items. The results were summarized, and after a final round of expert review, a selection of clinically relevant items for patients with lung cancer was made.

RESULTS

A heterogeneous group of patients with lung cancer (n=25) from different treatment modalities and HCPs (n=22) participated in the study. A final list of eight relevant PRO-CTCAE items was created: decreased appetite, cough, shortness of breath, fatigue, constipation, nausea, sadness, and pain (general).

CONCLUSIONS

On the basis of the literature and both professional and patient input, a subset of PRO-CTCAE items has been identified for use in patients with lung cancer in clinical practice. Future work is needed to confirm the validity and effectiveness of this PRO-CTCAE-based lung cancer subset internationally and in real-world clinical practice settings.

摘要

背景

患者报告的不良事件通用术语标准(PRO-CTCAE)项目库涵盖了与肿瘤护理相关的广泛症状。有必要选择与特定患者群体相关的项目子集,以便在临床实践中实施基于PRO-CTCAE的症状监测。

目的

本研究的目的是开发一个与肺癌患者相关的基于PRO-CTCAE的子集,可用于多学科临床实践中的监测。

方法

基于欧洲癌症研究与治疗组织制定问卷的指南,采用混合方法生成肺癌患者的基于PRO-CTCAE的子集,包括文献综述以及对肺癌患者和医疗保健从业者(HCP)的半结构化访谈。询问患者和HCP关于所有PRO-CTCAE项目的相关性和影响。总结结果,经过最后一轮专家评审后,选择了肺癌患者临床相关的项目。

结果

来自不同治疗方式的一组异质性肺癌患者(n=25)和HCP(n=22)参与了研究。创建了一份包含八个相关PRO-CTCAE项目的最终清单:食欲减退、咳嗽、气短、疲劳、便秘、恶心、悲伤和疼痛(全身)。

结论

基于文献以及专业人员和患者的意见,已确定了PRO-CTCAE项目的一个子集,用于肺癌患者的临床实践。未来需要开展工作,在国际上以及实际临床实践环境中确认这个基于PRO-CTCAE的肺癌子集的有效性和实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907a/8479599/d9c1b1ae5f47/cancer_v7i3e26574_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907a/8479599/a2772bbda515/cancer_v7i3e26574_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907a/8479599/d9c1b1ae5f47/cancer_v7i3e26574_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907a/8479599/a2772bbda515/cancer_v7i3e26574_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/907a/8479599/d9c1b1ae5f47/cancer_v7i3e26574_fig2.jpg

相似文献

1
Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study.基于患者报告的不良事件通用术语标准的肺癌治疗患者报告症状监测版本选择子集:混合方法研究
JMIR Cancer. 2021 Sep 14;7(3):e26574. doi: 10.2196/26574.
2
Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure.基于 PRO-CTCAE 的前列腺癌患者报告症状监测子集选择:一项改良 Delphi 程序。
ESMO Open. 2023 Feb;8(1):100775. doi: 10.1016/j.esmoop.2022.100775. Epub 2023 Jan 16.
3
Using a modified Delphi procedure to select a PRO-CTCAE-based subset for patient-reported symptomatic toxicity monitoring in rectal cancer patients.采用改良 Delphi 程序选择基于 PRO-CTCAE 的子集,用于监测直肠癌患者的患者报告症状毒性。
Qual Life Res. 2024 Nov;33(11):3013-3026. doi: 10.1007/s11136-024-03767-0. Epub 2024 Sep 8.
4
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国家癌症研究所患者报告结局版通用不良事件术语标准(PRO-CTCAE)的有效性和可靠性。
JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639.
5
Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.整合患者反馈与临床医生报告,以识别肝细胞癌特异性的治疗相关症状性不良事件亚组。
J Patient Rep Outcomes. 2018 Aug 22;2:35. doi: 10.1186/s41687-018-0063-4. eCollection 2017.
6
Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.美国国家癌症研究所患者报告结局通用术语标准不良事件的韩语版的可靠性和有效性。
J Pain Symptom Manage. 2020 May;59(5):1082-1088.e6. doi: 10.1016/j.jpainsymman.2020.01.015. Epub 2020 Feb 8.
7
Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology.解剖部位特异性患者报告结局版常见不良事件术语标准(PRO-CTCAE)用于评估放射肿瘤学急性症状毒性的项目集的内容效度。
Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):44-52. doi: 10.1016/j.ijrobp.2018.04.048. Epub 2018 Jun 5.
8
Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers.开发针对肿瘤的 PRO-CTCAE 项目集:在三家德国门诊癌症中心的横断面调查分析。
BMC Cancer. 2023 Jul 5;23(1):629. doi: 10.1186/s12885-023-11115-7.
9
Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.采用国家癌症研究所患者报告结局版通用不良事件术语标准评估肺动脉高压治疗耐受性:口服塞乐西帕的现用和曾用患者定性研究结果。
J Patient Rep Outcomes. 2023 Dec 18;7(1):134. doi: 10.1186/s41687-023-00673-w.
10
A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy.一种多方法结合的方式来选择 PRO-CTCAE 症状,以用于接受化疗的子宫内膜癌或卵巢癌女性的患者报告结局。
J Patient Rep Outcomes. 2023 Jul 18;7(1):72. doi: 10.1186/s41687-023-00611-w.

引用本文的文献

1
Beneficial value of [F]FDG PET/CT in the follow-up of patients with stage III non-small cell lung cancer (NVALT31-PET study): study protocol of a multicentre randomised controlled trial.[F]FDG PET/CT在Ⅲ期非小细胞肺癌患者随访中的有益价值(NVALT31-PET研究):一项多中心随机对照试验的研究方案
BMJ Open. 2025 Jul 25;15(7):e103745. doi: 10.1136/bmjopen-2025-103745.
2
Remote symptom monitoring with patient-reported outcomes and nudges during lung cancer immunotherapy in China (PRO-NET): protocol for a randomised controlled trial.中国肺癌免疫治疗期间通过患者报告结局和助推进行远程症状监测(PRO-NET):一项随机对照试验的方案
BMJ Open. 2025 Jan 28;15(1):e093374. doi: 10.1136/bmjopen-2024-093374.
3

本文引用的文献

1
Dutch translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™).美国国立癌症研究所不良事件通用术语标准患者报告结局版(PRO-CTCAE™)的荷兰语翻译及语言验证。
J Patient Rep Outcomes. 2020 Oct 6;4(1):81. doi: 10.1186/s41687-020-00249-y.
2
Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy.化疗或免疫治疗中膀胱癌患者的患者报告结局指标选择
J Patient Rep Outcomes. 2019 Aug 22;3(1):56. doi: 10.1186/s41687-019-0141-2.
3
The Value and Future Developments of Multidisciplinary Team Cancer Care.
Using a modified Delphi procedure to select a PRO-CTCAE-based subset for patient-reported symptomatic toxicity monitoring in rectal cancer patients.
采用改良 Delphi 程序选择基于 PRO-CTCAE 的子集,用于监测直肠癌患者的患者报告症状毒性。
Qual Life Res. 2024 Nov;33(11):3013-3026. doi: 10.1007/s11136-024-03767-0. Epub 2024 Sep 8.
4
Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial.患者主动与医生主动响应症状监测后的生活质量:SYMPRO-Lung 试验。
J Natl Cancer Inst. 2023 Dec 6;115(12):1515-1525. doi: 10.1093/jnci/djad159.
5
Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers.开发针对肿瘤的 PRO-CTCAE 项目集:在三家德国门诊癌症中心的横断面调查分析。
BMC Cancer. 2023 Jul 5;23(1):629. doi: 10.1186/s12885-023-11115-7.
6
SYMptom monitoring with Patient-Reported Outcomes using a web application among patients with Lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial.使用网络应用程序对荷兰肺癌患者进行症状监测并报告结果(SYMPRO-Lung):一项基于阶梯式随机对照试验的研究方案。
BMJ Open. 2021 Sep 13;11(9):e052494. doi: 10.1136/bmjopen-2021-052494.
多学科团队癌症护理的价值与未来发展
Am Soc Clin Oncol Educ Book. 2019 Jan;39:332-340. doi: 10.1200/EDBK_236857. Epub 2019 May 17.
4
Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy.为接受免疫治疗的转移性黑色素瘤患者选择反映症状的患者报告结局问题。
J Patient Rep Outcomes. 2019 Mar 21;3(1):19. doi: 10.1186/s41687-019-0111-8.
5
The use of PRO in adverse event identification during cancer therapy - choosing the right questions to ask.在癌症治疗期间使用 PRO 识别不良事件——选择正确的问题进行询问。
Acta Oncol. 2019 May;58(5):596-602. doi: 10.1080/0284186X.2018.1560496. Epub 2019 Jan 31.
6
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
7
Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology.解剖部位特异性患者报告结局版常见不良事件术语标准(PRO-CTCAE)用于评估放射肿瘤学急性症状毒性的项目集的内容效度。
Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):44-52. doi: 10.1016/j.ijrobp.2018.04.048. Epub 2018 Jun 5.
8
An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients.一项修订用于评估肺癌患者生活质量的 EORTC 问卷的国际研究。
Ann Oncol. 2017 Nov 1;28(11):2874-2881. doi: 10.1093/annonc/mdx453.
9
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.一项评估常规癌症治疗期间症状监测的患者报告结局的试验的总生存结果。
JAMA. 2017 Jul 11;318(2):197-198. doi: 10.1001/jama.2017.7156.
10
Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.随机试验比较肺癌患者的网络介导随访与常规监测。
J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx029.